Mitchell, Matthew
Hegde, Kausthubh
Som, Avik
Sutphin, Patrick
Kalva, Sanjeeva
Article History
Received: 12 June 2024
Revised: 4 November 2024
Accepted: 5 November 2024
First Online: 18 November 2024
Declarations
:
: Avik Som reports unrelated conflicts of interest including consulting income from Boston Scientific and Satellite Bio, has equity in Lightbeam health, and is on the board of directors for Sling Health. Sanjeeva P. Kalva reports grants from NIH, BD, Black Swan, and Trisalus for Institution; reports royalties from Elsevier, Springer, and Thieme for himself; reports consulting fees from Penumbra, Okami Medical, Boston Scientific, Medtronic, Instylla, and BD for himself; reports stock from Biogen Inc, Clover Health Investments Corp, Inovio Pharmaceuticals, Moderna Inc, Pfizer Inc, Novavax Inc, Orphazyme, Cassava Sciences Inc, Vivos Therapeutics Inc, Ardelyx Inc, Althea Health, Sarepta Therapeutics, Clover Health Investments Corp, CureVac BV, Immunoprecise Antibodies Ltd, Infinity Pharmaceuticals Inc, Zymergen Inc, BioNTech SE, Trillium Therapeutics Inc, Theravance Biopharma Inc, Doximity Inc, Eargo Inc, Allogent Therapeutics Inc, NRx Pharmaceuticals Inc, Atea pharmaceuticals Inc, for himself and spouse.The remaining authors declare no relevant conflicts of interest.